Patents Assigned to Yale University
-
Patent number: 11778995Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.Type: GrantFiled: August 21, 2020Date of Patent: October 10, 2023Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)Inventors: Richard Flavell, Till Strowig, Markus G. Manz, Chiara Borsotti, Madhav Dhodapkar, Andrew J. Murphy, Sean Stevens, George D. Yancopoulos
-
Patent number: 11782779Abstract: Techniques for quantum error correction of a multi-level system are provided and described. In some aspects, techniques for encoding a state of a multi-level quantum system include encoding a quantum information in a two-mode state of two quantum mechanical oscillators. Techniques for protecting the two-mode state against dephasing and energy loss are described.Type: GrantFiled: January 5, 2019Date of Patent: October 10, 2023Assignee: Yale UniversityInventors: Victor V. Albert, Shantanu Mundhada, Alexander Grimm, Steven Touzard, Michel Devoret, Liang Jiang
-
Patent number: 11779662Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.Type: GrantFiled: September 22, 2017Date of Patent: October 10, 2023Assignees: University of Rhode Island Board of Trustees, Yale UniversityInventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Publication number: 20230310534Abstract: A method for decreasing formation of one or more chemiexcitation-induced dark cyclobutane pyrimidine dimers (dCPDs) in a cell or DNA molecule in a subject, who has been exposed to UV radiation, is provided. The method comprises administering to the subject an effective amount of a dCPD quencher within 8 hours after the exposure. The dCPD quencher is selected from the group consisting of ellagic acid, Porphyra Umbilicalis Extract (including Porphyra Umbilicalis Extract (and) Sodium Lactate (and) Lecithin), mycosporine-like amino acids (MAAs) and synthetic analogues thereof, Scutellaria Baicalensis Root Extract, Chrysanthemum Morifolium Leaf Extract, ferulic acid, fused-ring cyanoacrylates, curcumin, epigallocatechin gallate, Scutellaria Baicalensis Root Extract (and) Acacia Catechu Wood Extract, sorbic acid, Polygonum Cuspidatum Root Extract, Acacia Catechu Extract, dipicolinic acid, squalene, Lonicera Japonica (Honeysuckle) Flower Extract, beta-carotene and combinations thereof.Type: ApplicationFiled: March 7, 2023Publication date: October 5, 2023Applicants: L'OREAL, Yale UniversityInventors: Kelly Marie GEORGE, Zhi PAN, Laurent MARROT, Miao WANG, Douglas Edgar BRASH, Sanjay PREMI, Leticia C.P. GONCALVES
-
Patent number: 11773096Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.Type: GrantFiled: August 9, 2019Date of Patent: October 3, 2023Assignee: YALE UNIVERSITYInventors: Ya Ha, Jonathan Ellman, Song Chen, Caroline Chandra Tjin, Fabrizio Micheli, Agostino Cianciulli, Claudia Beato
-
Patent number: 11771731Abstract: This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.Type: GrantFiled: April 6, 2022Date of Patent: October 3, 2023Assignee: YALE UNIVERSITYInventors: Shwu-Huey Liu, Zaoli Jiang, Yung-Chi Cheng
-
Patent number: 11766400Abstract: Biodegradable contraceptive implants and methods of making and using thereof, are preferably formed of poly(?-pentadecalactone-co-p-dioxanone) [poly(PDL-co-DO)], a family of polyester copolymers that degrade slowly in the presence of water. The material is suitable as the basis of a biodegradable contraceptive implant that provides sustained release of a progestin at a rate similar to a commercially available nondegradable implant. In a preferred embodiment, the progestin is levonorgestrel (LNG), a hormone that prevents pregnancy by preventing the release of an egg from the ovary or by preventing fertilization of the egg by sperm. The implant may be inserted subcutaneously, allowing degradation over a period of up to about 18 or 24 months, eliminating the need for removal by a trained practitioner.Type: GrantFiled: October 24, 2017Date of Patent: September 26, 2023Assignees: YALE UNIVERSITY, FAMILY HEALTH INTERNATIONALInventors: W. Mark Saltzman, Elias Quijano, Fan Yang, Zhaozhong Jiang, Derek Owen
-
Patent number: 11767301Abstract: The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are mediated through macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi-functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/IgG level in patients with autoimmune diseases or certain types of cancers.Type: GrantFiled: April 8, 2019Date of Patent: September 26, 2023Assignee: YALE UNIVERSITYInventors: David Spiegel, David Caianiello
-
Patent number: 11766032Abstract: Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function; in modeling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy.Type: GrantFiled: November 1, 2019Date of Patent: September 26, 2023Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)Inventors: Andrew J. Murphy, Sean Stevens, Richard Flavell, Markus Gabriel Manz, Liang Shan
-
Patent number: 11760708Abstract: The invention relates to novel, scalable synthetic routes that allow for direct reduction of enones to the corresponding saturated alcohols. The invention relates, in certain aspects, to synthetic routes that allow for the reduction of enones to the corresponding ketones. Such reactions take place under mild conditions, are compatible with a wide range of functional groups, and expand the repertoire of existing green chemistry methodology. In certain embodiments, the reactions are run in aqueous solvent.Type: GrantFiled: December 2, 2020Date of Patent: September 19, 2023Assignee: YALE UNIVERSITYInventors: Laurene Petitjean, Paul Thomas Anastas, Tamara Marie DeWinter, Philip Coish, Hanno Christian Erythropel, Predrag Petrovic
-
Publication number: 20230290467Abstract: The invention features methods that are useful for treatment of a patient at increased risk for infection and for selecting a patient for treatment for an infection. In various embodiments, the infection is coronavirus disease 2019 (COVID-19), sepsis, or other respiratory infections.Type: ApplicationFiled: March 14, 2023Publication date: September 14, 2023Applicants: The Broad Institute, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic, Yale University, The General Hospital CorporationInventors: Pradeep NATARAJAN, Giulio GENOVESE, Seyedeh Maryam ZEKAVAT, Mitchell J. MACHIELA, Shu-Hong LIN
-
Patent number: 11753743Abstract: Provided herein, in some embodiments, are devices, systems and methods for high-throughput single-cell polyomics (e.g., genomic, epigenomic, proteomic and/or phenotypic profile) analyses.Type: GrantFiled: February 13, 2018Date of Patent: September 12, 2023Assignee: Yale UniversityInventors: Rong Fan, Burak Dura
-
Publication number: 20230277658Abstract: Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.Type: ApplicationFiled: November 9, 2022Publication date: September 7, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Adele RICCIARDI, Raman BAHAL, Audrey TURCHICK, Nicholas ECONOMOS, W. Mark SALTZMAN, Peter GLAZER
-
Patent number: 11746111Abstract: In one aspect, the invention provides compounds and methods that are useful for treating bacterial infections:Type: GrantFiled: July 19, 2019Date of Patent: September 5, 2023Assignee: YALE UNIVERSITYInventors: Mark Plummer, Denton Hoyer, Elizabeth Spencer
-
Publication number: 20230272115Abstract: Compositions for enhanced gene editing and methods of use thereof are. The composition contains a cell-penetrating antibody and a donor oligonucleotide containing a sequence that can correct a mutation in a cell's genome. Preferably, the composition does not contain a nuclease, PNA, or nanoparticle. The compositions are used to modify the genome of a cell by contacting the cell with an effective amount of the composition. Genomic modification occurs at a higher frequency both ex vivo and in vivo, when cells are contacted with the cell-penetrating antibody and donor oligonucleotide as compared to the absence of the cell-penetrating antibody.Type: ApplicationFiled: November 9, 2022Publication date: August 31, 2023Applicant: Yale UniversityInventors: Elias QUIJANO, Audrey TURCHICK, Peter GLAZER
-
Patent number: 11739104Abstract: The present invention provides compositions and methods for inhibiting group II intron splicing for treating or preventing a disease or disorder associated with an organism harboring an active group II intron. The present invention also provides compositions and methods for inhibiting group II intron splicing for inhibiting, preventing or reducing growth of an organism harboring an active group II intron.Type: GrantFiled: January 25, 2019Date of Patent: August 29, 2023Assignee: YALE UNIVERSITYInventors: Anna Pyle, Olga Fedorova, Erik Gunnar Jagdmann, Michael Van Zandt, Lin Yuan, Albert DeBerardinis
-
Patent number: 11738096Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.Type: GrantFiled: September 22, 2017Date of Patent: August 29, 2023Assignees: Yale University, University of Rhode Island Board of TrusteesInventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Patent number: 11737376Abstract: A superconducting device includes two nodes and a Josephson junction coupled between the two nodes, wherein the Josephson junction is characterized by a superconducting phase difference, ?, wherein the superconducting device has a potential that varies as a function of the superconducting phase difference, ?, and has a single potential well. The potential has a non-zero cubic term and quartic term is zero. The Josephson junction may be a single small Josephson junction. The superconducting device may include a superconducting ring connected between the two nodes. The superconducting ring may include a first ring portion with a plurality of large Josephson junctions connected in series. The superconducting ring may also include a second ring portion that includes the single small Josephson junction in parallel with the plurality of large Josephson junctions between the two nodes.Type: GrantFiled: December 11, 2018Date of Patent: August 22, 2023Assignee: Yale UniversityInventors: Nicholas Frattini, Uri Vool, Shyam Shankar, Anirudh Narla, Katrina Sliwa, Michel Devoret, Volodymyr Sivak
-
Patent number: 11725064Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.Type: GrantFiled: May 17, 2021Date of Patent: August 15, 2023Assignee: YALE UNIVERSITYInventors: David Spiegel, Ryan Murelli, Andrew Zhang
-
Patent number: 11725204Abstract: Compositions and methods for gene editing are provided. The methods employ an oligo-based annealing mechanism that is rooted in the process of DNA replication rather than homologous recombination (HR). Oligo incorporation efficiencies are comparable and often exceed those of CRISPR/cas9 editing without the need for double strand breaks (DSBs). By relying on the multiplex annealing of oligos rather than DSBs the process is highly scalable across a genomic region of interest and can generate many scarless modifications of a chromosome simultaneously. Combinatorial genomic diversity can be generated across a population of cells in a single transformation event; genomic landscapes can be traversed through successive iterations of the process, and genome-wide changes can be massively parallelized and amplified through systematic strain mating.Type: GrantFiled: April 27, 2017Date of Patent: August 15, 2023Assignee: YALE UNIVERSITYInventors: Edward Barbieri, Farren Isaacs